Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115624 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Mariam Alexander und 34 weiteren Autor:innen. Beteiligte Einrichtung: Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: alexanma@musc.edu. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Patient Satisfaction, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen Research and Development, Johnson and Johnson.
Abstract (Originalsprache)
INTRODUCTION: Intravenous anticancer treatments present challenges for patients and healthcare professionals (HCPs), prompting the development of subcutaneous formulations. In the phase 3 PALOMA-3 study, subcutaneous amivantamab demonstrated noninferior pharmacokinetics and response rates versus intravenous amivantamab (both with lazertinib), with substantially faster administration, a 5-fold reduction in infusion-related reactions, reduced venous thromboembolism, and numerically prolonged survival. METHODS: Participants with EGFR-mutated NSCLC and progression on osimertinib and chemotherapy were randomized to subcutaneous (n = 206) or intravenous amivantamab (n = 212), plus lazertinib. Resource utilization and participant-reported treatment satisfaction were evaluated at cycle (C) 1 day (D) 1 and C3D1. RESULTS: Time-in-chair was substantially lower for subcutaneous versus intravenous amivantamab (C1D1: median [range], 23 min or 0.4 h [0-12.0 h] vs 6.5 h [0-24.0 h]; C3D1: 35 min or 0.6 h [0-6.6 h] vs 3.4 h [0.5-9.0 h]), as were HCP time and participant time-in-room. More participants who received subcutaneous versus intravenous amivantamab reported feeling unrestricted (C1D1, 66 % vs 29 %; C3D1, 60 % vs 42 %) or unbothered (C1D1, 69 % vs 30 %; C3D1, 71 % vs 45 %) by administration, and reported gaining time for other activities (C1D1, 36 % vs 7 %; C3D1, 37 % vs 6 %). Few participants who received subcutaneous amivantamab reported moderate-to-very severe injection-site pain (C1D1, 14 %; C3D1, 16 %), swelling (C1D1, 5 %; C3D1, 6 %), or redness (C1D1, 5 %; C3D1, 6 %). Most subcutaneous amivantamab recipients preferred and were more satisfied with its administration versus historical experience with intravenous therapies and would recommend it. CONCLUSIONS: In PALOMA-3, subcutaneous amivantamab, which simplifies and shortens administration, reduces resource utilization, and enhances treatment experience, was a preferred option for patients who received amivantamab-lazertinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: alexanma@musc.edu.
- Jilin Cancer Hospital, Changchun, China.
- Samsung Medical Center, Sungkyunkwan University Medical School, Seoul, Republic of Korea.
- Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.
- Virginia Cancer Specialists, Fairfax, VA, United States.
- Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
Förderung
- Janssen Research and Development
- Johnson and Johnson
Zitieren
APA
Alexander, M., Cheng, Y., Lee, S. H., Passaro, A., Spira, A. I., Cho, B. C., Lim, S. M., Ohe, Y., Nagrial, A., Tan, J. L., Wainsztein, V., Ramos, E., Campelo, M. D. R. G., Akamatsu, H., Nguyen, D., Cortot, A. B., Zer, A., Erdem, D., Sanborn, R. E., …, & Leighl, N. B. (2025). Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115624
Vancouver
Alexander M, Cheng Y, Lee SH, Passaro A, Spira AI, Cho BC, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115624
BibTeX
@article{Alexander2025,
author = {Alexander, Mariam and Cheng, Ying and Lee, Se-Hoon and Passaro, Antonio and Spira, Alexander I and Cho, Byoung Chul and Lim, Sun Min and Ohe, Yuichiro and Nagrial, Adnan and Tan, Jiunn Liang and Wainsztein, Vanina and Ramos, Elisa and Campelo, Maria Del Rosario Garcia and Akamatsu, Hiroaki and Nguyen, Danny and Cortot, Alexis B and Zer, Alona and Erdem, Dilek and Sanborn, Rachel E and Emde, Till-Oliver and Minchom, Anna R and Zurawski, Bogdan and Ferreira, Maria Lurdes and Yang, James Chih-Hsin and Marmarelis, Melina E and Schuchard, Julia and Alves, Jefferson and Ghosh, Debopriya and Balaburski, Gregor and Verheijen, Remy B and Ribeiro, Liliana and Gamil, Mohamed and Bauml, Joshua M and Baig, Mahadi and Leighl, Natasha B},
title = {Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115624}
}
EUVIMED